grant
Small Molecule ERG Inhibitors for Prostate Cancer
Organization UNIVERSITY OF VIRGINIALocation CHARLOTTESVILLE, UNITED STATESPosted 1 Jul 2024Deadline 30 Jun 2029
NIHUS FederalResearch GrantFY2025Allosteric SiteAndrogen ReceptorAnti-androgen TherapyAnti-androgen TreatmentApoptosisApoptosis PathwayAssayBasal Transcription FactorBasal transcription factor genesBindingBioassayBiochemicalBiologic ModelsBiological AssayBiological ModelsCancer PatientCancersCell BodyCell CycleCell DeathCell Division CycleCellsCessation of lifeChIP SequencingChIP-seqChIPseqChromatinChromosomal dislocationChromosomal translocationClinicCoupledDNA BindingDNA Binding InteractionDNA boundDataDeathDevelopmentDiseaseDisorderDrug KineticsDrug resistanceEndothelial CellsEpitheliasin GeneEvaluationFamilyFormulationGene ExpressionGene FusionGeneral Transcription Factor GeneGeneral Transcription FactorsGeneralized GrowthGenerationsGenesGenetic TranslocationGenomeGrantGrowthHumanImmune EvasionIn vivo analysisLigandsMalignant NeoplasmsMalignant TumorMalignant neoplasm of prostateMalignant prostatic tumorMedicalMiceMice MammalsModel SystemModern ManMolecular InteractionMurineMusNaturePDX modelPRO-seqPRSS10Patient derived xenograftPatientsPharmacokineticsPrecision Run-On SequencingPrecision nuclear run-on sequencingProductionPrognosisProgrammed Cell DeathProliferatingPropertyProstate CAProstate CA therapyProstate CancerProstate Cancer therapyProstate malignancyProteinsReactionRecurrenceRecurrentResistance developmentResistant developmentRoleSpecificityStructure-Activity RelationshipSystemTMPRSS2TMPRSS2 geneTestingTherapeutic Steroid HormoneTissue GrowthTissue ModelToxic effectToxicitiesTranscriptTranscription Factor Proto-OncogeneTranscription factor genesWorkandrogen ablation therapyandrogen blockade therapyandrogen deprivation therapyandrogen deprivation treatmentandrogen independent prostate cancerandrogen indifferent prostate cancerandrogen insensitive prostate cancerandrogen resistance in prostate cancerandrogen resistant prostate cancerantagonismantagonistcancer cell stemnesscancer diagnosiscancer stem cell likecancer stemnesscastration resistant CaPcastration resistant PCacastration resistant prostate cancercellular targetingchemical structure functionchemoproteomicschromatin immunoprecipitation coupled with sequencingchromatin immunoprecipitation followed by sequencingchromatin immunoprecipitation with sequencingchromatin immunoprecipitation-seqchromatin immunoprecipitation-sequencingchromosome dislocationchromosome translocationcohortcommercializationdetermine efficacydeveloping resistancedevelopmentaldrug developmentdrug resistantefficacy analysisefficacy assessmentefficacy determinationefficacy evaluationefficacy examinationefficacy studyevaluate efficacyexamine efficacygenome scalegenome-widegenomewidehormone refractory prostate cancerimmune evasiveimprovedin vivoin vivo evaluationin vivo testinginhibitormalemalignancymembermenmetermigrationnano-molarnanomolarnecrocytosisneoplasm/cancernew therapeutic approachnew therapeutic interventionnew therapeutic strategiesnew therapy approachesnew treatment approachnew treatment strategynovelnovel therapeutic approachnovel therapeutic interventionnovel therapeutic strategiesnovel therapy approachontogenyoverexpressoverexpressionpatient derived xenograft modelpre-clinical evaluationpreclinical evaluationprostate cancer cell lineprostate cancer modelprostate cancer resistant to androgenprostate cancer treatmentprostate tumor modelresistance to Drugresistant to Drugresponseside effectsmall molecular inhibitorsmall moleculesmall molecule inhibitorsocial rolestandard of carestemness in cancersteroid hormonestructure function relationshiptherapeutic targettranscription factortranslational pipelinetranslational spectrum♂
Description preview
Project Summary/Abstract
There is a critical need for more effective and durable prostate cancer treatments. Prostate cancer (PCa) is the
most frequently diagnosed cancer among men and the second leading cause of male cancer deaths in the US.
The development, progression, and recurrence of PCa is dependent on the Androgen Receptor (AR). This has…
🔒
Start 7-day free trial — $29.99/mo →Full details available on the Agency plan
Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.
Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click